Searched for
STEMPEUTICS
Stempeutics gets DCGI nod for Phase 3 clinical trial on its product for treating COVID patientsStempeucel exhibits potent immuno-modulatory and anti-inflammatory properties which could help in reducing the inflammation caused due to t...- Stempeutics Research receives patent for critical limb ischemia treatment method"The US patent is for the method of treating ischemia by administering pooled allogeneic mesenchymal stromal cells," Stempeutics Research s...
- Stempeutics partners with Cipla for its stem cell drugFounded in 2006 by Manipal Education and Medical Group (MEMG), Stempeutics later entered into an alliance with Cipla in 2009. It is an adva...
- Stempeutics research gets DCGI nod for stem cell based productThe company's goal is to globalise Stempeucel for Buerger's Disease and the market size is approximately $ 1.5 billion worldwide.
- Stempeutics plans stem cell device launch in India by mid 2016The company is looking for a strategic partner to globalise and market this device in India and outside.
- Cipla's Stempeutics gets process patent for Stempeucel from JapanStempeutics has received process patent from the Japan for novel stem cell drug Stempeucel aimed at treatment of critical limb ischemia.
- Stempeutics' Stempeucel gets Orphan Drug status in EuropeAn orphan designation allows a company to benefit from incentives from the European Union to develop a medicine for a rare disease.
- Indian biotech firm Stempeutics Research gets China Patent for its novel stem cell drugStempeutics' stem cell-based drugs enable living tissues to repair or replace tissue or organ function lost due to age, disease, damage or ...
- Stempeutics gets EMA approval to market stem cell drug in EUThe ATMP classification, approved by the committee for Advanced Therapies (CAT) of the EMA will allow the Bengaluru- based Stempeutics to c...
- Cipla rallies nearly 3% on getting US patent for stemcell productAt 09:40 a.m.; Cipla was trading 2.4 per cent higher at Rs 742.20. It hit a low of Rs 725 and a high of Rs 744.90 in trade today.
- Indian biotech firm Stempeutics Research gets US Process Patent for its novel stem cell drugBacked by the Manipal Education and Medical Group and drug maker Cipla, Stempeutics makes stem cell-based drugs or regenerative medicine.
- Azim Premji set to buy 10% in Manipal Education for Rs 900 crorePremjiInvest, the proprietary investment fund of the Wipro chairman, is in the final lap of deal making, which could be announced soon.
- Startups do promising work in drug development, stem cell therapy and advanced diagnosticsDemand for quality healthcare and easier access to capital have led to the launch of many startups working in such areas as new drug develo...
- Power of Ideas 2012: How made-in-India medical tech startups save lives across bordersSpanning areas such as medical devices, stem cells and next generation drugs, a group of startups is creating breakthrough innovations that...
- Cipla hopeful of achieving 12-15 per cent revenue growth in FY13Pharma major Cipla Ltd today said it is hopeful of achieving 12-15 per cent revenue growth in the current financial year.
- Cipla to invest Rs 500 cr to set up API facilitiesCipla Ltd plans to invest Rs 500 crore for setting up an active pharmaceutical ingredients (API) facilities at Patalganga, Bengaluru and Ku...
- Biocon to invest $161 mn in MalaysiaBiocon will invest $161 million in a facility in Malaysia, joining a number of Indian companies that have chosen to establish facilities in...
- Malaysia calling for Indian biotech cosIndian biotech companies are increasingly looking to make major investments in Malaysia, lured by the south-east Asian country's tax sops.
- DCGI gives approval to Stempeutics ResearchThe drug controller general of India (DCGI) has given approval to Stempeutics Research, a Manipal Group company, for conducting clinical tr...
- Two Indian firms to set up pre-clinical trials units in MalaysiaTwo companies from south India are in the final stages of establishing pre-clinical trial facilities in Malaysia, which has been aggressive...
Load More
